Revisiting the role of glucagon in health, diabetes mellitus and other metabolic diseases

Modeling the Amino Acid Effect on Glucagon Secretion from Pancreatic Alpha Cells

(2022) Jan Zmazek et al.   Metabolites

The Liver-Alpha Cell Axis in Health and in Disease

(2022) Michael M. Richter et al.   DIABETES

Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial

(2022) Jeremy Pettus et al.   NATURE MEDICINE

Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice

(2022) Patrick J. Knerr et al.   Molecular Metabolism

Glucagonostatic Potency of GLP-1 in Patients with Type 2 Diabetes, in Patients with Type 1 Diabetes and in Healthy Controls

(2021) Jonatan I. Bagger et al.   DIABETES

Effects of endogenous GIP in patients with type 2 diabetes

(2021) Signe Stensen et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Exendin(9‐39) NH 2 : Recommendations for clinical use based on a systematic literature review

(2021) Lærke Smidt Gasbjerg et al.   DIABETES OBESITY & METABOLISM

Glucagon Clearance Is Preserved in Type 2 Diabetes

(2021) Magnus F.G. Grøndahl et al.   DIABETES

Glucagon Resistance at the Level of Amino Acid Turnover in Obese Subjects with Hepatic Steatosis

(2020) Malte P. Suppli et al.   DIABETES

No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes

(2020) Natasha C. Bergmann et al.   DIABETES CARE

GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals

(2020) Lærke S Gasbjerg et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The Role of α-Cells in Islet Function and Glucose Homeostasis in Health and Type 2 Diabetes

(2020) Patrick Gilon   JOURNAL OF MOLECULAR BIOLOGY

Alanine, arginine, cysteine, and proline but not glutamine are substrates for and acute mediators of the liver-alpha cell axis in female mice

(2020) Katrine D. Galsgaard et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Blood Flow in the Pancreatic Islet: Not so Isolated Anymore

(2020) Joana Almaça et al.   DIABETES

The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition

(2020) Sofie Hædersdal et al.   DIABETES

The mediation by GLP-1 receptors of glucagon-induced insulin secretion revisited in GLP-1 receptor knockout mice

(2020) Bo Ahrén et al.   PEPTIDES

The liver-alpha cell axis and type 2 diabetes

(2019) Nicolai J Wewer Albrechtsen et al.   ENDOCRINE REVIEWS

Glucose controls glucagon secretion by directly modulating cAMP in alpha cells

(2019) Qian Yu et al.   DIABETOLOGIA

Glucagon Receptor Signaling and Lipid Metabolism

(2019) Katrine D. Galsgaard et al.   Frontiers in Physiology

Repositioning Glucagon Action in the Physiology and Pharmacology of Diabetes

(2019) Brian Finan et al.   DIABETES

1952-P: Glucagon Receptor Antagonism Increases Plasma Amino Acids and Glucagon

(2019) SOFIE HAEDERSDAL et al.   DIABETES

Investigating Intestinal Glucagon after Roux-en-Y Gastric Bypass Surgery

(2019) Tina Jorsal et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion—A Review

(2019) David S. Mathiesen et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Glucagon Control on Food Intake and Energy Balance

(2019) Omar Al-Massadi et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

A Primary Role for Alpha Cells as Amino Acid Sensors

(2019) E. Danielle Dean   DIABETES

Methods and Guidelines for Measurement of Glucagon in Plasma

(2019) Jens J. Holst et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Structural basis for delta cell paracrine regulation in pancreatic islets

(2019) Rafael Arrojo e Drigo et al.   Nature Communications

The Local Paracrine Actions of the Pancreatic Alpha Cell

(2019) Rayner Rodriguez-Diaz et al.   DIABETES

Disruption of glucagon receptor signaling causes hyperaminoacidemia exposing a possible liver-alpha-cell axis

(2018) Katrine D. Galsgaard et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Hyperglucagonemia correlates with plasma levels of non-branched-chain amino acids in patients with liver disease independent of type 2 diabetes

(2018) Nicolai J. Wewer Albrechtsen et al.   AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY

Paracrine Interactions within the Pancreatic Islet Determine the Glycemic Set Point

(2018) Rayner Rodriguez-Diaz et al.   Cell Metabolism

Individual and Combined Glucose-Lowering Effects of Glucagon Receptor Antagonism and Dipeptidyl Peptidase-4 Inhibition

(2018) SOFIE HAEDERSDAL et al.   DIABETES

Glucagon Receptor Antagonist LGD-6972 Significantly Lowers HbA1c and Is Well Tolerated after 12-Week Treatment in Patients with Type 2 Diabetes Mellitus (T2DM) on Metformin

(2018) JEREMY PETTUS et al.   DIABETES

Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: A randomized controlled trial

(2018) Jeremy Pettus et al.   DIABETES OBESITY & METABOLISM

Efficacy and Safety of the Glucagon Receptor Antagonist PF-06291874: A 12-Week, Randomized, Dose-Response Study in Patients With Type 2 Diabetes Mellitus on Background Metformin Therapy

(2018) David J. Kazierad et al.   DIABETES OBESITY & METABOLISM

Extrapancreatic glucagon: present status

(2018) Asger Lund et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Evidence of a liver–alpha cell axis in humans: hepatic insulin resistance attenuates relationship between fasting plasma glucagon and glucagonotropic amino acids

(2018) Nicolai J. Wewer Albrechtsen et al.   DIABETOLOGIA

EJE PRIZE 2018: A gut feeling about glucagon

(2018) Filip K Knop   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Hemodynamic Effects of Glucagon: A Literature Review

(2018) Kasper Meidahl Petersen et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Urea cycle dysregulation in non-alcoholic fatty liver disease

(2018) Francesco De Chiara et al.   JOURNAL OF HEPATOLOGY

MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study

(2018) Philip Ambery et al.   LANCET

The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes

(2018) Sofie Hædersdal et al.   MAYO CLINIC PROCEEDINGS

The somatostatin-secreting pancreatic δ-cell in health and disease

(2018) Patrik Rorsman et al.   Nature Reviews Endocrinology

Oxyntomodulin: Actions and role in diabetes

(2018) Jens J. Holst et al.   PEPTIDES

Human pancreatic α- to β-cell area ratio increases after type 2 diabetes onset

(2018) Yukari Fujita et al.   Journal of Diabetes Investigation

A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials

(2018) Joachim Tillner et al.   DIABETES OBESITY & METABOLISM

GLP-1 Receptor in Pancreatic α-Cells Regulates Glucagon Secretion in a Glucose-Dependent Bidirectional Manner

(2018) Yanqing Zhang et al.   DIABETES

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

(2018) Juan Pablo Frias et al.   LANCET

The α-cell in diabetes mellitus

(2018) Jesper Gromada et al.   Nature Reviews Endocrinology

Insulin Secretion Depends on Intra-islet Glucagon Signaling

(2018) Berit Svendsen et al.   Cell Reports

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

(2018) Tamer Coskun et al.   Molecular Metabolism

The New Biology and Pharmacology of Glucagon

(2017) T. D. Müller et al.   PHYSIOLOGICAL REVIEWS

Circulating Glucagon 1-61 Regulates Blood Glucose by Increasing Insulin Secretion and Hepatic Glucose Production

(2017) Nicolai J. Wewer Albrechtsen et al.   Cell Reports

Clinical Trials, Triumphs, and Tribulations of Glucagon Receptor Antagonists

(2016) Mackenzie J. Pearson et al.   DIABETES CARE

Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes

(2016) Giuseppe Daniele et al.   DIABETES CARE

Effects of DPP-4 inhibitor linagliptin and GLP-1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: A randomized, open-label, 2-arm parallel comparative, exploratory trial

(2016) Daisuke Yabe et al.   DIABETES OBESITY & METABOLISM

Glucagon is the key factor in the development of diabetes

(2016) Young H. Lee et al.   DIABETOLOGIA

Higher Endogenous Glucose Production During OGTT vs Isoglycemic Intravenous Glucose Infusion

(2016) Asger Lund et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effects of glucagon-like peptide-1 on glucagon secretion in patients with non-alcoholic fatty liver disease

(2016) Anders E. Junker et al.   JOURNAL OF HEPATOLOGY

DNA immunization combined with scFv phage display identifies antagonistic GCGR specific antibodies and reveals new epitopes on the small extracellular loops

(2016) Bas van der Woning et al.   mAbs

Involvement of steatosis-induced glucagon resistance in hyperglucagonaemia

(2016) Malte P. Suppli et al.   MEDICAL HYPOTHESES

Glucose control of glucagon secretion—‘There’s a brand-new gimmick every year’

(2016) Erik Gylfe   UPSALA JOURNAL OF MEDICAL SCIENCES

Changes in Levels of Biomarkers Associated with Adipocyte Function and Insulin and Glucagon Kinetics During Treatment with Dapagliflozin Among Obese Type 2 Diabetes Mellitus Patients

(2016) Aki Okamoto et al.   Drugs in research & development

Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion

(2016) Nicolai J. Wewer Albrechtsen et al.   Journal of Diabetes Research

The 2-monoacylglycerol moiety of dietary fat appears to be responsible for the fat-induced release of GLP-1 in humans

(2015) Mette J Mandøe et al.   AMERICAN JOURNAL OF CLINICAL NUTRITION

Somatostatin and insulin mediate glucose-inhibited glucagon secretion in the pancreatic α-cell by lowering cAMP

(2015) Amicia D. Elliott et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

The role of efferent cholinergic transmission for the insulinotropic and glucagonostatic effects of GLP-1

(2015) Astrid Plamboeck et al.   AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY

Hepatic Acetyl CoA Links Adipose Tissue Inflammation to Hepatic Insulin Resistance and Type 2 Diabetes

(2015) Rachel J. Perry et al.   CELL

Evidence of Extrapancreatic Glucagon Secretion in Man

(2015) Asger Lund et al.   DIABETES

Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies

(2015) Christof M. Kazda et al.   DIABETES CARE

Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes

(2015) R. P. Kelly et al.   DIABETES OBESITY & METABOLISM

The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial

(2015) Caroline K. Kramer et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Human Islet Morphology Revisited

(2015) Susan Bonner-Weir et al.   JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY

Glucagon Couples Hepatic Amino Acid Catabolism to mTOR-Dependent Regulation of α-Cell Mass

(2015) Mark J. Solloway et al.   Cell Reports

Pancreatic Alpha Cells Hold the Key to Survival

(2015) Jibran A. Wali et al.   EBioMedicine

Pancreatic α Cells are Resistant to Metabolic Stress-induced Apoptosis in Type 2 Diabetes

(2015) Laura Marroqui et al.   EBioMedicine

Glucose-Dependent Insulinotropic Polypeptide Augments Glucagon Responses to Hypoglycemia in Type 1 Diabetes

(2014) Mikkel Christensen et al.   DIABETES

Coinfusion of Low-Dose GLP-1 and Glucagon in Man Results in a Reduction in Food Intake

(2014) Jaimini Cegla et al.   DIABETES

Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels?

(2014) Nicolai J. Wewer Albrechtsen et al.   DIABETOLOGIA

Glucagon responses to increasing oral loads of glucose and corresponding isoglycaemic intravenous glucose infusions in patients with type 2 diabetes and healthy individuals

(2014) Jonatan I. Bagger et al.   DIABETOLOGIA

Postprandial Dynamics of Plasma Glucose, Insulin, and Glucagon in Patients with Type 2 Diabetes Treated with Saxagliptin Plus Dapagliflozin Add-On to Metformin Therapy

(2014) Lars Hansen et al.   Endocrine Practice

Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production

(2014) Aurora Merovci et al.   JOURNAL OF CLINICAL INVESTIGATION

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

(2014) Ele Ferrannini et al.   JOURNAL OF CLINICAL INVESTIGATION

A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents

(2014) Brian Finan et al.   NATURE MEDICINE

Role of KATP Channels in Glucose-Regulated Glucagon Secretion and Impaired Counterregulation in Type 2 Diabetes

(2013) Quan Zhang et al.   Cell Metabolism

Glucose regulation of glucagon secretion

(2013) Erik Gylfe et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Glucose-dependent Insulinotropic Polypeptide: Blood Glucose Stabilizing Effects in Patients With Type 2 Diabetes

(2013) Mikkel B. Christensen et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Glucagon regulates ACC activity in adipocytes through the CAMKKβ/AMPK pathway

(2012) I-Chen Peng et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets

(2012) P. Marchetti et al.   DIABETOLOGIA

Transcriptional Regulation of N-Acetylglutamate Synthase

(2012) Sandra Kirsch Heibel et al.   PLoS One

The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes

(2011) Asger Lund et al.   AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM

Remodeling of Hepatic Metabolism and Hyperaminoacidemia in Mice Deficient in Proglucagon-Derived Peptides

(2011) C. Watanabe et al.   DIABETES

Glucose-Dependent Insulinotropic Polypeptide: A Bifunctional Glucose-Dependent Regulator of Glucagon and Insulin Secretion in Humans

(2011) M. Christensen et al.   DIABETES

Growth factor signalling in the regulation of α-cell fate

(2011) D. Kawamori et al.   DIABETES OBESITY & METABOLISM

Regulation of glucagon secretion by incretins

(2011) J. J. Holst et al.   DIABETES OBESITY & METABOLISM

Regulation of glucagon secretion by glucose: paracrine, intrinsic or both?

(2011) J. N. Walker et al.   DIABETES OBESITY & METABOLISM

Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity

(2011) F. K. Knop et al.   DIABETES OBESITY & METABOLISM

Alpha cells secrete acetylcholine as a non-neuronal paracrine signal priming beta cell function in humans

(2011) Rayner Rodriguez-Diaz et al.   NATURE MEDICINE

 -Aminobutyric Acid (GABA) Is an Autocrine Excitatory Transmitter in Human Pancreatic  -Cells

(2010) M. Braun et al.   DIABETES

Effects of Acute Hyperglucagonemia on Hepatic and Intestinal Lipoprotein Production and Clearance in Healthy Humans

(2010) C. Xiao et al.   DIABETES

The Glucagonostatic and Insulinotropic Effects of Glucagon-Like Peptide 1 Contribute Equally to Its Glucose-Lowering Action

(2010) K. J. Hare et al.   DIABETES

Unique Arrangement of  - and  -Cells in Human Islets of Langerhans

(2010) D. Bosco et al.   DIABETES

The Effect on Glucagon, Glucagon-Like Peptide-1, Total and Acyl-Ghrelin of Dietary Fats Ingested with and without Potato

(2010) Angela Radulescu et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The metabolic actions of glucagon revisited

(2010) Kirk M. Habegger et al.   Nature Reviews Endocrinology

Glucagon regulation of energy metabolism

(2010) Kristy M. Heppner et al.   PHYSIOLOGY & BEHAVIOR

Intraislet production of GLP-1 by activation of prohormone convertase 1/3 in pancreatic α-cells in mouse models of β-cell regeneration

(2010) German Kilimnik et al.   Islets

Insulin Signaling in α Cells Modulates Glucagon Secretion In Vivo

(2009) Dan Kawamori et al.   Cell Metabolism

Exogenous Glucose-Dependent Insulinotropic Polypeptide Worsens Post prandial Hyperglycemia in T ype 2 Diabetes

(2009) C. W. Chia et al.   DIABETES

Resolution of type 2 diabetes following gastric bypass surgery: involvement of gut-derived glucagon and glucagonotropic signalling?

(2009) F. K. Knop   DIABETOLOGIA

Vildagliptin Enhances Islet Responsiveness to Both Hyper- and Hypoglycemia in Patients with Type 2 Diabetes

(2009) Bo Ahrén et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Differential expression of glucagon and glucagon-like peptide 1 receptors in mouse pancreatic alpha and beta cells in two models of alpha cell hyperplasia

(2009) Mamdouh H. Kedees et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

The Glucagon Receptor Is Required for the Adaptive Metabolic Response to Fasting

(2008) Christine Longuet et al.   Cell Metabolism

Glucose and Pharmacological Modulators of ATP-Sensitive K+ Channels Control [Ca2+]c by Different Mechanisms in Isolated Mouse  -Cells

(2008) N. Quoix et al.   DIABETES

Somatostatin Secreted by Islet  -Cells Fulfills Multiple Roles as a Paracrine Regulator of Islet Function

(2008) A. C. Hauge-Evans et al.   DIABETES

Long-term exposure of mouse pancreatic islets to oleate or palmitate results in reduced glucose-induced somatostatin and oversecretion of glucagon

(2008) S. C. Collins et al.   DIABETOLOGIA

Insulin secretion from human beta cells is heterogeneous and dependent on cell-to-cell contacts

(2008) A. Wojtusciszyn et al.   DIABETOLOGIA

The incretin system and its role in type 2 diabetes mellitus

(2008) J HOLST et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Interleukin-6 regulates pancreatic  -cell mass expansion

(2008) H. Ellingsgaard et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA